GlassScriptPhysician profile
Arthur M Lubitz
NPI 1437348471
$164,798.35
in general payments reported to CMS, 2019-2025
37 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $15K · 2021: $18K · 2022: $32K · 2023: $22K · 2024: $33K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $17K · Consulting Fee: $6,800 · Travel and Lodging: $3,969 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,611.25 |
| Food and Beverage | $17,404.78 |
| Consulting Fee | $6,800.00 |
| Travel and Lodging | $3,969.01 |
| Education | $115.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $74,420.51 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Incyte Corporation | $31,911.63 | 2021-2025 | Opzelura, Opzelura |
| Optinose US, INC. | $17,879.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $8,583.99 | 2019-2025 | |
| Mylan Specialty L.P. | $8,364.87 | 2019-2022 | |
| Glaxosmithkline, LLC. | $6,445.77 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $4,453.25 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,514.87 | 2019-2022 | |
| Genentech USA, INC. | $1,618.27 | 2019-2024 | Xolair |
| Regeneron Healthcare Solutions, INC. | $1,189.66 | 2019-2025 | Dupixent |
| Abbvie INC. | $1,065.76 | 2022-2025 | |
| Regeneron Pharmaceuticals, INC. | $802.71 | 2019-2025 | Dupixent |
| Alk-Abello, INC | $707.49 | 2019-2022 | |
| Leo Pharma INC. | $596.44 | 2022-2025 | Adbry, Anzupgo |
| Csl Behring | $595.34 | 2019-2025 | Haegarda, Kcentra, Andembry |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Lubitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.